AlphAIAlphAI — Financial news for AI agents
stocktitan.net$CARL

A live call on Carlsmed's quarterly results starts at 1:30 p.m. Pacific on Nov. 10.

Carlsmed, Inc. (Nasdaq: CARL) will release its Q3 2026 financial results on Nov. 10, 2026, after market close. A conference call and webcast will follow at 1:30 PM Pacific Time. The company focuses on AI-enabled personalized spine surgery solutions.

Original reporting
stocktitan.net
Published Oct 27, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 8:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$CARL
Neutral
high confidence
Mentioned
$CARL
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$CARLNeutralLow
01

Why it matters

The call announcement sets the timeline for the next earnings release but adds no substantive data.

02

Market read

The article is a routine earnings‑release notice with limited immediate trading impact.

03

What to watch

Potential hidden catalyst such as a regulatory update or partnership could be announced during the call.

Relevance 4/10Novelty 4/10Timing: pre-market on Nov 10, 2026

Background

Carlsmed is a Nasdaq‑listed medical‑technology firm focused on AI‑enabled spine‑surgery solutions.

Company-level read

Ticker impact

$CARLNeutralHigh confidence
Context

Carlsmed announced it will report its Q3 2026 earnings on Nov 10, 2026 and host a live conference call.

Expected impact

neutral pending the earnings release

Evidence & confidence

The article provides only a schedule announcement without numbers, so traders have no immediate directional cue.

Market effects

Sector

None disclosed; the announcement does not affect the broader medical technology sector.

Regional

None

Global

Limited to investors tracking Carlsmed's upcoming earnings.

Counterpoint

What could challenge this read

Without guidance, the stock could be more volatile than expected on the earnings day.

Key entities

  • Company
    Carlsmed, Inc.

    Medical technology company (NASDAQ: CARL).

Read at source← All news

Related articles

$CARLHigh

Carlsmed (CARL) Q3 2026 Earnings Call Transcript

Carlsmed (CARL) reported 65% revenue growth in Q3 2026, raising full-year guidance to $78M-$80M. The company launched new products and expects 2027 catalysts. Management updates include new COO, CFO, and Chief Product & AI Officer. Clinical data shows reduced reoperation rates, and new reimbursement codes may boost hospital adoption.

finance.yahoo.com
$CARLMed

Carlsmed Q3 Earnings Call Highlights

Carlsmed (NASDAQ:CARL) plans to enroll patients in a registry for its aprevo Cervical product in Q4. The company expects a change in reimbursement coding to boost lumbar procedure growth. Carlsmed launched its aprevo posterior bilateral procedure in mid-October and plans to launch its corra cervical plating system soon. Q3 gross margin improved to 77.3%, but adjusted EBITDA remained negative at -$7.3M. The company ended Q3 with $80.3M in cash and investments.

finance.yahoo.com
$CARLHigh

Carlsmed® Reports Third Quarter 2026 Financial Results and Raises Full-Year Guidance

CARLSMED, INC. (CARL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Carlsmed ® Reports Third Quarter 2026 Financial Results and Raises Full-Year Guidance Third quarter 2026 revenue of $21.6 million, representing 65% growth year-over-year Full year 2026 revenue guidance raised to $78 million to $80 million CARLSBAD, CALIFORNIA, NOVEMBER 10, 2026 (

SEC EDGAR 8-K